{
    "organizations": [],
    "uuid": "c63e7ad3a4d9ab48209a69e840f64c004ebc4fe4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-spero-therapeutics-reports-q1-loss/brief-spero-therapeutics-reports-q1-loss-per-share-0-74-idUSASC0A1L3",
    "ord_in_thread": 0,
    "title": "BRIEF-Spero Therapeutics Reports Q1 Loss Per Share $0.74",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Spero Therapeutics Inc:\n* SPERO THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE UPDATE\n* Q1 LOSS PER SHARE $0.74 * Q1 EARNINGS PER SHARE VIEW $-1.20 â€” THOMSON REUTERS I/B/E/S\n* PLANS TO INITIATE A PIVOTAL PHASE 3 CLINICAL TRIAL OF SPR994 FOR TREATMENT OF CUTI AROUND YEAR-END 2018 IN SUPPORT OF A NDA\n* EXPECTS THAT ITS RESEARCH AND DEVELOPMENT EXPENSES WILL INCREASE THROUGH 2018\n* BELIEVES THAT ITS EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND OPERATIONS THROUGH LATE IN Q2 OF 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T04:50:00.000+03:00",
    "crawled": "2018-05-11T12:49:36.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "spero",
        "therapeutic",
        "inc",
        "spero",
        "therapeutic",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "pipeline",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "plan",
        "initiate",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "spr994",
        "treatment",
        "cuti",
        "around",
        "support",
        "nda",
        "expects",
        "research",
        "development",
        "expense",
        "increase",
        "belief",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "fund",
        "operation",
        "late",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}